Literature DB >> 8287885

New prognostic factors in prostatic carcinoma.

T Visakorpi1, O P Kallioniemi, T Koivula, J Isola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8287885     DOI： 10.1159/000474347

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  5 in total

1.  Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization.

Authors:  T Visakorpi; E Hyytinen; A Kallioniemi; J Isola; O P Kallioniemi
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

2.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.

Authors:  Shen Gao; Peng Lee; Hua Wang; William Gerald; Michael Adler; Liying Zhang; Yun-Fang Wang; Zhengxin Wang
Journal:  Mol Endocrinol       Date:  2005-02-24

3.  Expression of matrix metalloproteinase-10 in non-metastatic prostate cancer: Correlation with an imbalance in cell proliferation and apoptosis.

Authors:  Sugure Maruta; Yasuyoshi Miyata; Yuji Sagara; Shigeru Kanda; Takahisa Iwata; Shin-Ichi Watanabe; Hideki Sakai; Tomayoshi Hayashi; Hiroshi Kanetake
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

4.  Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Authors:  P Koivisto; E Hyytinen; C Palmberg; T Tammela; T Visakorpi; J Isola; O P Kallioniemi
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

5.  Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer.

Authors:  T Jørgensen; K Yogesan; F Skjørten; A Berner; K J Tveter; H E Danielsen
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.